Clinical Trial

Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms

Study acronym: FINAL
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-18.
Trial Details
NCT Number NCT07665749
Lead Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Benign Prostate Hypertrophy(BPH)
Enrollment 50 participants
Start Date 2026-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-26